How to Measure an Innovation Portfolio

If measuring a single innovation asks whether one idea is working, measuring a portfolio asks a different question: is the whole collection of bets, taken together, on track to deliver the growth you're counting on, even though many of the individual bets won't make it? A portfolio isn't measured by adding up its projects. It's measured as a population, against an objective the population as a whole is meant to achieve.

That distinction is where most "innovation portfolios" come apart. As we've written in The Uncomfortable Truth About Your Innovation Portfolio Strategy, many are a single big bet dressed up as a diversified strategy, or just a pipeline of projects with no strategic intent behind the mix. In both cases there's nothing to measure at the portfolio level, because there's no portfolio, only a list.

Start from the portfolio objective

As with any scope, measurement begins with the objective. A portfolio objective is the specific set of growth outcomes leadership can be held accountable to: revenue contribution by a given year, entry into named adjacencies, defensive coverage against particular disruption threats. It can span the kinds of value any single innovation might create, from near-term financial to long-term strategic, but it's stated for the population, not the project. Without it, there's no basis for judging whether the mix of bets is the right one.

What "measured as a population" means

Once the objective is set, a portfolio's health shows up in a handful of population-level reads, each tracked as actual performance against an intentional target:

• Allocation. How resources are distributed across the portfolio, by class of innovation and over time. Is the investment actually going where the strategy says it should?
• Balance. Whether the mix across core, adjacent, and disruptive classes of innovation matches the intended targets, rather than quietly drifting back toward the safe and familiar.
• Survival. How projects advance and fall out stage by stage, measured against the expected funnel. In a healthy portfolio most early ideas are stopped and the few that reach the late stages are expected to launch; that decline-then-rise pattern is a designed feature, not a sign of failure, and the metric is actual survival against the modeled expectation.
• Contribution. The rolled-up revenue and profit each class is expected to add toward the objective, and whether the portfolio as a whole still sums to the growth ambition.

Underneath all of these sits an interdependence that project-level measurement can't see: a decision to continue or stop any one project is implicitly a decision about the resources available to every other project. You can only weigh that trade-off from the portfolio altitude.

Model the expected portfolio, then manage to it

The reason a portfolio can be measured this precisely is that its expected behavior can be modeled before the fact. Each class of innovation has a profile, its expected investment, time, survival rate, and revenue characteristics. Run those ranged assumptions across the portfolio and you get expected distributions for investment over time, contribution by class, and survival by stage, which become the targets managers actually manage against.

That is what BRI's Growth Forge® Portfolio Modeling Tool is built to do: it simulates over per-class cashflow models to turn a portfolio strategy from a narrative into quantified expectations, paired with dashboards that track the real portfolio against those targets. Its origin explains the point of the exercise. The tool grew out of a forecast model built inside a corporate innovation practice to expose the math of portfolio fallout, so leaders could see in numbers why pulling resources back toward the core would cost them the long-term growth they'd committed to. Measuring the portfolio quantitatively is what keeps that commitment honest.

Rebalancing and termination are part of the measurement

A portfolio you never rebalance isn't being managed; it's being watched. The discipline that gives the metrics teeth is acting on them: setting evidence requirements and investment limits per stage, holding real termination protocols so weak bets are stopped and their resources redeployed, and rebalancing on a regular rhythm as evidence arrives. Continue, Pivot, Pause, and Stop are portfolio decisions as much as project ones, because each one reallocates capacity across the whole population.

In practice

Measuring an innovation portfolio comes down to a sequence: name the objective for the population, model its expected behavior across classes, track the real portfolio against that model on allocation, balance, survival, and contribution, and rebalance as the evidence moves. Do that and the portfolio becomes something leadership can govern deliberately rather than hope about, which is the whole reason to run one. It's also the bridge to the broadest scope of all, the organization's standing capability to keep producing portfolios like it, and it's what our consulting work and Growth Forge® Software are built to make repeatable.

BRI Associates helps companies grow by drawing on decades of practitioner experience in corporate innovation and new business development — practitioners, not pundits or academics — through direct consulting, training workshops, and Growth Forge® Software, built for the unique requirements of corporate innovation and growth organizations.